Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

This is a Non-interventional, Prospective, Multicenter Study Conducted in France. The Primary Objective of This Study is to Describe the Quality of Life of MS Patients After Initiation of Treatment With Ofatumumab.

NCT06157086 is registered in ClinicalTrials.gov with Novartis Pharmaceuticals as lead sponsor.

NCT NCT06157086
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06157086 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
This is a Non-interventional, Prospective, Multicenter Study Conducted in France. The Primary Objective of This Study is to Describe the Quality of Life of MS Patients After Initiation of Treatment With Ofatumumab.
Lead sponsor
Novartis Pharmaceuticals
Phase
Observational
Overall status
Active, not recruiting
Start date
December 21, 2023
Completion date
July 31, 2026
Enrollment
302 (actual)
Sites
49

Conditions

As the registry lists them; a condition with its own page is linked.

multiple sclerosis (ms)